# Andreas du Bois

Source: https://onco.cc/people/andreas-du-bois/  
OnCo record `andreas-du-bois` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Surgeon who chairs the German AGO group and led DESKTOP III, proving secondary surgery can extend survival in selected relapsed ovarian cancer.

## Summary

Andreas du Bois (Kliniken Essen-Mitte) chairs the AGO ovarian cancer study group, whose trials established carboplatin-paclitaxel as standard and defined the prognostic value of complete cytoreduction. He was principal investigator of DESKTOP III, which showed secondary cytoreductive surgery improves overall survival in AGO-score-positive platinum-sensitive relapse, and of the TRUST trial of primary versus interval surgery.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: ovarian; surgery; cooperative-group
- Role: Director of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte; Chair, AGO Study Group
- Specialisms: Ovarian cancer surgery; Cooperative-group trials; Cytoreductive surgery; Chemotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=du%20Bois%20A%5BAuthor%5D%20ovarian%20DESKTOP

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- institutions: [Kliniken Essen-Mitte](https://onco.cc/institutions/kliniken-essen-mitte/)
- trials: [DESKTOP III / ENGOT-ov20](https://onco.cc/trials/desktop-iii/)
- journals: [Cancer](https://onco.cc/journals/cancer-wiley/)

---
JSON: https://onco.cc/api/v1/entities/andreas-du-bois.json